3Takashi Fujimura M.D.,Yutaka Yonemura M.D.,Keiichi Muraoka M.D.,Hiroyuki Takamura M.D.,Yasuo Hirono M.D.,Hiroyuki Sahara M.D.,Itasu Ninomiya M.D.,Hisashi Matsumoto M.D.,Kouichiro Tsugawa M.D.,Gen-ichi Nishimura M.D.,Kazuo Sugiyama M.D.,Kouichi Miwa M.D.,Itsuo Miyazaki M.D.. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: Randomized controlled study[J] 1994,World Journal of Surgery(1):150～155
4Yutaka Yonemura M.D.,Takashi Fujimura M.D.,Sachio Fushida M.D.,Shigeru Takegawa M.D.,Toru Kamata M.D.,Kanji Katayama M.D.,Takeo Kosaka M.D.,Akio Yamaguchi M.D.,Kouichi Miwa M.D.,Ituo Miyazaki M.D.. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination[J] 1991,World Journal of Surgery(4):530～535
6Daly MB, Ozols RF. Symptoms of ovarian cancer-Where to set the bar[J].JAMA, 2004, 291 (22):2755-2756.
7Harter P, du Bois A. The role of surgery in ovarian cancer with spe- cial emphasis on cytoreductive surgery for recurrence[J]. Curr Opin Oncol. 2005. 17:505-514.
8Ferrandina G, Legge F, Salutari V, et al. Impact of pattern of recur- rence on clixfical outcome of ovarian cancer patients: clinical consid- erations[J]. EurJ Cancer, 2006, 42:2296-2302.
9PfistererJ, LedermnnJA. Mangement of platinum-Sensitive Recurrent Ovarian Cancer[J]. Seminars in Oncology, 2006, 33(2 suppl 6):12-16.
10Rose PG, BlessingJA, Ball HG, et al. A phase II study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma: a Gynecologic Oneology Group study[J]. Gynecol Oncol, 2003, 88(2):130-135.
